Sana Biotechnology, Inc.

What they do

Sana Biotechnology is developing two platform technologies: ex vivo hypoimmune (HIP) cells for allogeneic transplantation and in vivo fusogens for cell-specific delivery of genetic payloads. Lead programs are SC451, a HIP-modified stem cell-derived pancreatic islet cell therapy for type 1 diabetes, and SG293, a CD8-targeted fusosome delivering CD19 CAR T cells for B cell malignancies and autoimmune diseases. The company also has SG227, a CD8-targeted fusosome delivering BCMA-directed CAR T cells for multiple myeloma.

Revenue drivers

• SC451 (type 1 diabetes) — No revenue; pre-revenue clinical candidate. HIP-modified islet cell therapy aiming for euglycemia without insulin or immunosuppression.
• SG293 (B cell malignancies and autoimmune diseases) — No revenue; pre-revenue clinical candidate. In vivo CAR T delivery, expected to enter clinical trials as early as 2026.
• SG227 (multiple myeloma) — No revenue; pre-revenue preclinical candidate. BCMA-directed CAR T fusosome, expected to begin clinical study as early as mid-2027.
• Collaborations and licensing — Minimal revenue; primarily collaborations like Mayo Clinic for type 1 diabetes, but no licensing revenue reported.

Recent performance

For Q2 2026, cash position was $160.5 million, consisting of $61.3 million in cash, cash equivalents, and restricted cash plus $103.4 million in marketable securities. The company recorded expenses of $7.6 million and $5.2 million in the three and six months ended June 30, 2026, respectively, related to changes in fair value of success payment liabilities. Net losses have narrowed annually from $355.9 million in 2021 to $244.2 million in 2025, with diluted EPS improving from -$2.14 to -$0.96 over the same period. As of June 30, 2026, total assets were $431.5 million, total liabilities $277.0 million, and shareholder equity $154.6 million.

Strategy

The company is advancing two lead programs into clinical trials: SC451 for type 1 diabetes and SG293 for non-Hodgkin lymphoma, with initial data expected as early as 2026. It is leveraging its HIP technology to enable allogeneic cell transplantation without immunosuppression, as demonstrated by UP421 data in an investigator-sponsored study. The in vivo CAR T platform aims to simplify manufacturing and avoid lymphodepleting chemotherapy. They are also expanding into additional indications, including B cell-mediated autoimmune diseases and multiple myeloma with SG227. Cash runway is expected into mid-2027.

Risks

• Clinical execution risk — SC451 and SG293 are early-stage; INDs and Phase 1/2 trials are expected but not yet filed or started, with data generation uncertain.
• Cash runway limited — As of June 30, 2026, cash and marketable securities total $160.5 million, expected to fund operations only into mid-2027, requiring additional financing.
• Success payment liabilities volatility — The estimated fair value of success payment liabilities was $24.5 million, and changes in market capitalization or stock price can cause significant expense swings, as illustrated by hypothetical 20% changes.
• Regulatory and manufacturing challenges — SC451 is undergoing GLP toxicology studies and process transfer to a contract manufacturer, with risks of delay or failure in scale-up and regulatory approval.

Outlook

Management expects to file an IND and begin a Phase 1/2 trial for SC451 as early as 2026, and to generate first-in-human data for SG293 in non-Hodgkin lymphoma as early as 2026. They also expect to begin a clinical study for SG227 in multiple myeloma as early as mid-2027. The company projects cash runway into mid-2027.